The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Novel approaches to bridging prior to CAR-T therapy in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, addresses the challenge of bridging therapy to CAR-T in multiple myeloma (MM). Given the resistance often encountered in this heavily pretreated population, Dr Richardson underscores the need for innovative approaches to disease control with minimal toxicity. He highlights several novel agents, including cereblon E3 ligase modulators (CELMoDs), selinexor, and melflufen-based bridging therapies. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda, Oncopeptides, Celgene/BMS, Karyopharm, Takeda.
